

Publications that have used Enroll-HD data

1. McNally G, Rickards H, Horton M, Craufurd D. **Exploring the Validity of the Short Version of the Problem Behaviours Assessment (PBA-s) for Huntington's disease: A Rasch Analysis.** J Huntingtons Dis. 2015;4(4):347-69. doi: 10.3233/JHD-150164. PMID: 26756591.
2. Bettencourt C, Hensman-Moss D, Flower M, Wiethoff S, Brice A, Goizet C, Stevanin G, Koutsis G, Karadima G, Panas M, Yescas-Gómez P, García-Velázquez LE, Alonso-Vilatela ME, Lima M, Raposo M, Traynor B, Sweeney M, Wood N, Giunti P; SPATAX Network, Durr A, Holmans P, Houlden H, Tabrizi SJ, Jones L. **DNA repair pathways underlie a common genetic mechanism modulating onset in polyglutamine diseases.** Ann Neurol. 2016 Jun;79(6):983-90. doi: 10.1002/ana.24656. PMID: 27044000; PMCID: PMC4914895.
3. Landwehrmeyer GB, Fitzer-Attas CJ, Giuliano JD, Gonçalves N, Anderson KE, Cardoso F, Ferreira JJ, Mestre TA, Stout JC, Sampaio C. **Data Analytics from Enroll-HD, a Global Clinical Research Platform for Huntington's Disease.** Mov Disord Clin Pract. 2016 Jun 22;4(2):212-224. doi: 10.1002/mdc3.12388. PMID: 30363395; PMCID: PMC6174428.
4. Frich JC, Rae D, Roxburgh R, Miedzybrodzka ZH, Edmondson M, Pope EB, Goodman L, Haddad MS, Giuliano J, Nelson EC, Guttman M, Nance M. **Health Care Delivery Practices in Huntington's Disease Specialty Clinics: An International Survey.** J Huntingtons Dis. 2016 Jun 27;5(2):207-13. doi: 10.3233/JHD-160192. PMID: 27372053; PMCID: PMC4942722.
5. Schultz JL, Kamholz JA, Moser DJ, Feely SM, Paulsen JS, Nopoulos PC. **Substance abuse may hasten motor onset of Huntington disease: Evaluating the Enroll-HD database.** Neurology. 2017 Feb 28;88(9):909-915. doi: 10.1212/WNL.0000000000003661. PMID: 28148631; PMCID: PMC5331869.
6. Hervás D, Fornés-Ferrer V, Gómez-Escribano AP, Sequedo MD, Peiró C, Millán JM, Vázquez-Manrique RP. **Metformin intake associates with better cognitive function in patients with Huntington's disease.** PLoS One. 2017 Jun 20;12(6):e0179283. doi: 10.1371/journal.pone.0179283. PMID: 28632780; PMCID: PMC5478119.
7. Walker T, Ghosh B, Kipps C. **Assessing Decline: Visualising Progression in Huntington's Disease using a Clinical Dashboard with Enroll-HD Data.** J Huntingtons Dis. 2017;6(2):139-147. doi: 10.3233/JHD-170234. PMID: 28550266.
8. Ghosh S, Sun Z, Li Y, Cheng Y, Mohan A, Sampaio C, Hu J. **An Exploration of Latent Structure in observational Huntington's Disease Studies.** AMIA Jt Summits Transl Sci Proc. 2017 Jul 26;2017:92-102. PMID: 28815114; PMCID: PMC5543350.
9. van der Burg JMM, Gardiner SL, Ludolph AC, Landwehrmeyer GB, Roos RAC, Aziz NA. **Body weight is a robust predictor of clinical progression in Huntington disease.** Ann Neurol. 2017 Sep;82(3):479-483. doi: 10.1002/ana.25007. PMID: 28779551.
10. Kringlen G, Kinsley L, Aufox S, Rouleau G, Bega D. **The Impact of Family History on the Clinical Features of Huntington's Disease.** J Huntingtons Dis. 2017;6(4):327-335. doi: 10.3233/JHD-170256. PMID: 28984613.

Publications that have used Enroll-HD data

11. Winder JY, Roos RAC. **Premanifest Huntington's disease: Examination of oculomotor abnormalities in clinical practice.** PLoS One. 2018 Mar 1;13(3):e0193866. doi: 10.1371/journal.pone.0193866. eCollection 2018. PMID: 29494703; PMCID: PMC5832368.
12. Sun Z, Li Y, Ghosh S, Cheng Y, Mohan A, Sampaio C, Hu J. **A Data-Driven Method for Generating Robust Symptom Onset Indicators in Huntington's Disease Registry Data.** AMIA Annu Symp Proc. 2018 Apr 16; 2017:1635-1644. PMID: 29854234.
13. Schultz JL, Nopoulos PC, Gonzalez-Alegre P. **Human Immunodeficiency Virus Infection in Huntington's Disease is Associated with an Earlier Age of Symptom Onset.** J Huntingtons Dis. 2018;7(2):163-166. doi: 10.3233/JHD-180287. PMID: 29843248.
14. Aziz NA, van der Burg JMM, Tabrizi SJ, Landwehrmeyer GB. **Overlap between age-at-onset and disease-progression determinants in Huntington disease.** Neurology. 2018 Jun 12;90(24): e2099-e2106. doi: 10.1212/WNL.0000000000005690. PMID: 29743208; PMCID: PMC5996832.
15. Schultz JL, Killoran A, Nopoulos PC, Chabal CC, Moser DJ, Kamholz JA. **Evaluating depression and suicidality in tetrabenazine users with Huntington disease.** Neurology. 2018 Jul 17;91(3): e202-e207. doi: 10.1212/WNL.0000000000005817. PMID: 29925548.
16. Barkhuizen M, Rodrigues FB, Anderson DG, Winkens B; REGISTRY Investigators of the European Huntington's Disease Network, Wild EJ, Kramer BW, Gavilanes AWD. **Perinatal insults and neurodevelopmental disorders may impact Huntington's disease age of diagnosis.** Parkinsonism Relat Disord. 2018 Oct; 55:55-60. doi: 10.1016/j.parkreldis.2018.05.016. PMID: 29804730; PMCID: PMC6226577.
17. Fusilli C, Migliore S, Mazza T, Consoli F, De Luca A, Barbagallo G, Ciammola A, Gatto EM, Cesarini M, Etcheverry JL, Parisi V, Al-Oraimi M, Al-Harrasi S, Al-Salmi Q, Marano M, Vonsattel JG, Sabatini U, Landwehrmeyer GB, Squitieri F. **Biological and clinical manifestations of juvenile Huntington's disease: a retrospective analysis.** Lancet Neurol. 2018 Nov;17(11):986-993. doi: 10.1016/S1474-4422(18)30294-1. PMID: 30243861.
18. Honrath P, Dogan I, Wudarczyk O, Görlich KS, Votinov M, Werner CJ, Schumann B, Overbeck RT, Schulz JB, Landwehrmeyer BG, Gur RE, Habel U, Reetz K; Enroll-HD investigators. **Risk factors of suicidal ideation in Huntington's disease: literature review and data from Enroll-HD.** J Neurol. 2018 Nov;265(11):2548-2561. doi: 10.1007/s00415-018-9013-6. PMID: 30167880.
19. Rocha NP, Mwangi B, Gutierrez Candano CA, Sampaio C, Furr Stimming E, Teixeira AL. **The Clinical Picture of Psychosis in Manifest Huntington's Disease: A Comprehensive Analysis of the Enroll-HD Database.** Front Neurol. 2018 Nov 6;9:930. doi: 10.3389/fneur.2018.00930. PMID: 30459704; PMCID: PMC6232301.
20. Long JD, Mills JA. **Joint modeling of multivariate longitudinal data and survival data in several observational studies of Huntington's disease.** BMC Med Res Methodol. 2018 Nov 16;18(1):138. doi: 10.1186/s12874-018-0592-9. PMID: 30445915; PMCID: PMC6240282.

Publications that have used Enroll-HD data

21. Watkins K, Purks J, Kumar A, Sokas RK, Heller H, Anderson KE. **Huntington's Disease and Employment: The Relative Contributions of Cognitive and Motor Decline to the Decision to Leave Work.** J Huntingtons Dis. 2018;7(4):367-377. doi: 10.3233/JHD-180296. PMID: 30198875.
22. Schultz JL, Kamholz JA, Nopoulos PC, Killoran A. **Comparing Risperidone and Olanzapine to Tetrabenazine for the Management of Chorea in Huntington Disease: An Analysis from the Enroll-HD Database.** Mov Disord Clin Pract. 2018 Nov 30;6(2):132-138. doi: 10.1002/mdc3.12706. eCollection 2019 Feb. PMID: 30838312; PMCID: PMC6384174.
23. Gatto E, Parisi V, Persi G, Fernandez Rey E, Cesarini M, Luis Etcheverry J, Rivera P, Squitieri F. **Optical coherence tomography (OCT) study in Argentinean Huntington's disease patients.** Int J Neurosci. 2018 Dec;128(12):1157-1162. doi: 10.1080/00207454.2018.1489807. PMID: 29912591.
24. Scarabino D, Veneziano L, Peconi M, Frontali M, Mantuano E, Corbo RM. **Leukocyte telomere shortening in Huntington's disease.** J Neurol Sci. 2019 Jan 15;396:25-29. doi: 10.1016/j.jns.2018.10.024. PMID: 30396032.
25. Schultz JL, Nopoulos PC, Killoran A, Kamholz JA. **Statin use and delayed onset of Huntington's disease.** Mov Disord. 2019 Feb;34(2):281-285. doi: 10.1002/mds.27591. PMID: 30576007.
26. Castaldo I, De Rosa M, Romano A, Zuchegna C, Squitieri F, Mechelli R, Peluso S, Borrelli C, Del Mondo A, Salvatore E, Vescovi LA, Migliore S, De Michele G, Ristori G, Romano S, Avvedimento EV, Porcellini A. **DNA damage signatures in peripheral blood cells as biomarkers in prodromal huntington disease.** Ann Neurol. 2019 Feb;85(2):296-301. doi: 10.1002/ana.25393. PMID: 30549309.
27. Yu M, Tan K, Koloms K, Bega D. **Assessment of Caregiver Burden in Huntington's Disease.** J Huntingtons Dis. 2019;8(1):111-114. doi: 10.3233/JHD-180326. PMID: 30594932.
28. Goold R, Flower M, Moss DH, Medway C, Wood-Kaczmar A, Andre R, Farshim P, Bates GP, Holmans P, Jones L, Tabrizi SJ. **FAN1 modifies Huntington's disease progression by stabilizing the expanded HTT CAG repeat.** Hum Mol Genet. 2019 Feb 15;28(4):650-661. doi: 10.1093/hmg/ddy375. PMID: 30358836; PMCID: PMC6360275.
29. Sun Z, Ghosh S, Li Y, Cheng Y, Mohan A, Sampaio C, Hu J. **A probabilistic disease progression modeling approach and its application to integrated Huntington's disease observational data.** JAMIA Open. 2019 Jan 7;2(1):123-130. doi: 10.1093/jamiaopen/ooy060. PMID: 31984350; PMCID: PMC6951948.
30. Rojas NG, Ziliani JE, Cesarini ME, Etcheverry JL, Da Prat GA, McCusker E, Gatto EM. **Late Onset Huntington Disease: Phenotypic and Genotypic Characteristics of 10 Cases in Argentina.** J Huntingtons Dis. 2019;8(2):195-198. doi: 10.3233/JHD-180330. PMID: 31045517.
31. Shahn Z, Li Y, Sun Z, Mohan A, Sampaio C, Hu J. **G-Computation and Hierarchical Models for Estimating Multiple Causal Effects From Observational Disease Registries With Irregular Visits.** AMIA Jt Summits Transl Sci Proc. 2019 May 6; 2019:789-798. PMID: 31259036.
32. Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, Wild EJ, Saft C, Barker RA, Blair NF, Craufurd D, Priller J, Rickards H, Rosser A, Kordasiewicz HB, Czech C, Swayze EE, Norris DA, Baumann T, Gerlach I, Schobel SA, Paz E, Smith AV, Bennett CF, Lane RM; Phase 1–2a IONIS-HTTRx Study Site Teams. **Targeting Huntingtin**

Publications that have used Enroll-HD data

- Expression in Patients with Huntington's Disease.** N Engl J Med. 2019 Jun 13;380(24):2307-2316. doi: 10.1056/NEJMoa1900907. PMID: 31059641.
33. Flower M, Lomeikaite V, Ciosi M, Cumming S, Morales F, Lo K, Hensman Moss D, Jones L, Holmans P; TRACK-HD Investigators; OPTIMISTIC Consortium, Monckton DG, Tabrizi SJ. **MSH3 modifies somatic instability and disease severity in Huntington's and myotonic dystrophy type 1.** Brain. 2019 Jun 19. pii: awz115. doi: 10.1093/brain/awz115. PMID: 31216018; PMCID: PMC6598626.
 34. Bartoszek A, Aubeeluck A, Stuppel E, Bartoszek A, Kocka K, Ślusarska B. **Exploring the Reliability and Validity of the Huntington's Disease Quality of Life Battery for Carers (HDQoL-C) within A Polish Population.** Int J Environ Res Public Health. 2019 Jun 30;16(13). pii: E2323. doi: 0.3390/ijerph16132323. PMID: 31262100; PMCID: PMC6651847.
 35. Zeitler B, Froelich S, Marlen K, Shivak DA, Yu Q, Li D, Pearl JR, Miller JC, Zhang L, Paschon DE, Hinkley SJ, Ankoudinova I, Lam S, Guschin D, Kopan L, Cherone JM, Nguyen HB, Qiao G, Ataei Y, Mendel MC, Amora R, Surosky R, Laganieri J, Vu BJ, Narayanan A, Sedaghat Y, Tillack K, Thiede C, Gärtner A, Kwak S, Bard J, Mrzljak L, Park L, Heikkinen T, Lehtimäki KK, Svedberg MM, Häggkvist J, Tari L, Tóth M, Varrone A, Halldin C, Kudwa AE, Ramboz S, Day M, Kondapalli J, Surmeier DJ, Urnov FD, Gregory PD, Rebar EJ, Muñoz-Sanjuán I, Zhang HS. **Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington's disease.** Nat Med. 2019 Jul;25(7):1131-1142. doi: 10.1038/s41591-019-0478-3. PMID: 31263285.
 36. Aubeeluck A, Stuppel EJN, Schofield MB, Hughes AC, van der Meer L, Landwehrmeyer B, Ho AK. **An International Validation of a Clinical Tool to Assess Carers' Quality of Life in Huntington's Disease.** Front Psychol. 2019 Jul 23;10:1658. doi: 10.3389/fpsyg.2019.01658. PMID: 31402885; PMCID: PMC6676956.
 37. Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium. Electronic address: gusella@helix.mgh.harvard.edu; Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium. **CAG Repeat Not Polyglutamine Length Determines Timing of Huntington's Disease Onset.** Cell. 2019 Aug 8;178(4):887-900.e14. doi: 10.1016/j.cell.2019.06.036. PMID: 31398342.
 38. Li F, Li K, Li C, Luo S; PREDICT-HD and ENROLL-HD Investigators of the Huntington Study Group. **Predicting the Risk of Huntington's Disease with Multiple Longitudinal Biomarkers.** J Huntingtons Dis. 2019;8(3):323-332. doi: 10.3233/JHD-190345. PMID: 31256145; PMCID: PMC6718328.
 39. Yomtoob J, Yeh C, Bega D. **Ancillary Service Utilization and Impact in Huntington's Disease.** J Huntingtons Dis. 2019;8(3):301-310. doi: 10.3233/JHD-190349. PMID: 31177235.
 40. Drew CJG, Quinn L, Hamana K, Williams-Thomas R, Marsh L, Dimitropoulou P, Playle R, Griffin BA, Kelson M, Schubert R, Muratori L, Reilmann R, Rosser A, Busse M. **Physical Activity and Exercise Outcomes in Huntington Disease (PACE-HD): Protocol for a 12-Month Trial Within Cohort Evaluation of a Physical Activity Intervention in People With Huntington Disease.** Phys Ther. 2019 Sep 1;99(9):1201-1210. doi: 10.1093/ptj/pzz075. PMID: 31101920.
 41. Ciosi M, Maxwell A, Cumming SA, Hensman Moss DJ, Alshammari AM, Flower MD, Durr A, Leavitt BR, Roos RAC; TRACK-HD team; Enroll-HD team, Holmans P, Jones L, Langbehn DR, Kwak S, Tabrizi SJ, Monckton DG. **A genetic association study of glutamine-encoding DNA sequence structures, somatic**

Publications that have used Enroll-HD data

CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes.

EBioMedicine. 2019 Oct 4. pii: S2352-3964(19)30624-3. doi: 10.1016/j.ebiom.2019.09.020. PMID: 31607598.

42. Julayanont P, McFarland NR, Heilman KM. **Mild cognitive impairment and dementia in motor manifest Huntington's disease: Classification and prevalence.** J Neurol Sci. 2020 Jan 15;408:116523 doi: 10.1016/j.jns.2019.116523. PMID: 31678902.
43. Ellis N, Tee A, McAllister B, Massey T, McLauchlan D, Stone T, Correia K, Loupe J, Kim KH, Barker D, Hong EP, Chao MJ, Long JD, Lucente D, Vonsattel JPG, Pinto RM, Elneel KA, Ramos EM, Mysore JS, Gillis T, Wheeler VC, Medway C, Hall L, Kwak S, Sampaio C, Ciosi M, Maxwell A, Chatzi A, Monckton DG, Orth M, Landwehrmeyer GB, Paulsen JS, Shoulson I, Myers RH, van Duijn E, Rickards H, MacDonald ME, Lee JM, Gusella JF, Jones L, Holmans P. **Genetic Risk Underlying Psychiatric and Cognitive Symptoms in Huntington's Disease.** Biol Psychiatry. 2020 May 1;87(9):857-865. doi: 10.1016/j.biopsych.2019.12.010. PMID: 32087949.
44. De Lucia N, Peluso S, Roca A, De Michele G, Trojano L, Salvatore E. **Perseverative Behavior on Verbal Fluency Task in Patients with Huntington's Disease: a Retrospective Study on a Large Patient Sample.** Arch Clin Neuropsychol. 2019 Dec 8. pii: acz052. doi: 10.1093/arclin/acz052. PMID: 31813981.
45. Julayanont P, Heilman KM, McFarland NR. **Early-motor phenotype relates to neuropsychiatric and cognitive disorders in huntington's disease.** Mov Disord. 2020 Jan 10. doi: 10.1002/mds.27980. PMID: 31922295.
46. Fazio P, Fitzer-Attas CJ, Mrzljak L, Bronzova J, Nag S, Warner JH, Landwehrmeyer B, Al-Tawil N, Halldin C, Forsberg A, Ware J, Dilda V, Wood A, Sampaio C, Varrone A; PEARL-HD and LONGPDE10 study collaborators. **PET molecular imaging of phosphodiesterase 10A: An early biomarker of Huntington's disease progression.** Mov Disord. 2020 Jan 22. doi: 10.1002/mds.27963. PMID: 31967355.
47. Steventon JJ, Rosser AE, Hart E, Murphy K. **Hypertension, Antihypertensive Use and the Delayed-Onset of Huntington's Disease.** Mov Disord. 2020 Feb 4. doi: 10.1002/mds.27976. PMID: 32017180.
48. Gaßner H, Jensen D, Marxreiter F, Kletsch A, Bohlen S, Schubert R, Muratori LM, Eskofier B, Klucken J, Winkler J, Reilmann R, Kohl Z. **Gait variability as digital biomarker of disease severity in Huntington's disease.** J Neurol. 2020 Feb 11. doi: 10.1007/s00415-020-09725-3. PMID: 32048014.
49. Gunn S, Maltby J, Dale M. **Assessing Mental Health Difficulties of Persons With Huntington's Disease: Does Informant Presence Make a Difference?** J Neuropsychiatry Clin Neurosci. 2020 Feb 7: appineuropsych19080181. doi: 10.1176/appi.neuropsych.19080181. PMID: 32102601.
50. Goh AMY, You E, Perin S, Lautenschlager NT, Clay FJ, Loi SM, Chong T, Ames D, Chiu E, Ellis KA. **Alcohol Use, Mental Health, and Functional Capacity as Predictors of Workplace Disability in a Cohort With Manifest Huntington's Disease.** J Neuropsychiatry Clin Neurosci. 2020 Feb 7: appineuropsych19090199. doi: 10.1176/appi.neuropsych.19090199. PMID: 32102602.
51. Harris KL, Kuan WL, Mason SL, Barker RA. **Antidopaminergic treatment is associated with reduced chorea and irritability but impaired cognition in Huntington's disease (Enroll-HD).** J Neurol Neurosurg Psychiatry. 2020 Mar 30. pii: jnnp-2019-322038. doi: 10.1136/jnnp-2019-322038. PMID: 32229581.

Publications that have used Enroll-HD data

52. Witkowski G, Jachinska K, Stepniak I, Ziara-Jakutowicz K, Sienkiewicz-Jarosz H. **Alterations in transcranial sonography among Huntington's disease patients with psychiatric symptoms.** J Neural Transm (Vienna). 2020 Apr 13. doi: 10.1007/s00702-020-02187-x. PMID: 32285254.
53. Schultz JL, Harshman LA, Langbehn DR, Nopoulos PC. **Hypertension Is Associated with an Earlier Age of Onset of Huntington's Disease.** Mov Disord. 2020 Apr 27. doi: 10.1002/mds.28062. PMID: 32339315.
54. Mills JA, Long JD, Mohan A, Ware JJ, Sampaio C. **Cognitive and Motor Norms for Huntington's Disease.** Arch Clin Neuropsychol. 2020 May 14. pii: acaa026. doi: 10.1093/arclin/acaa026. PMID: 32407458.
55. Achenbach J, von Hein SM, Saft C. **Functional and cognitive capacity differ in dystonic motor subtypes when compared to choreatic and hypokinetic-rigid motor subtypes in Huntington's disease.** Brain Behav. 2020 Jun 12: e01704. doi: 10.1002/brb3.1704. PMID: 32530575.
56. Yhnell E, Furby H, Lowe RS, Brookes-Howell LC, Drew CJG, Playle R, Watson G, Metzler-Baddeley C, Rosser AE, Busse ME. **A randomised feasibility study of computerised cognitive training as a therapeutic intervention for people with Huntington's disease (CogTrainHD).** Pilot Feasibility Stud. 2020 Jun 19;6:88. doi: 10.1186/s40814-020-00623-z. PMID: 32577299.
57. Steventon JJ, Furby H, Ralph J, O'Callaghan P, Rosser AE, Wise RG, Busse M, Murphy K. **Altered cerebrovascular response to acute exercise in patients with Huntington's disease.** Brain Commun. 2020;2(1):fcaa044. doi: 10.1093/braincomms/fcaa044. PMID: 32566927.
58. Jaini A, Yomtoob J, Yeh C, Bega D. **Understanding HD Psychosis: An Analysis from the ENROLL-HD Database.** Tremor Other Hyperkinet Mov (N Y). 2020 Jul 7;10:16. doi: 10.5334/tohm.395. PMID: 32775030.
59. Kwa L, Larson D, Yeh C, Bega D. **Influence of Age of Onset on Huntington's Disease Phenotype.** Tremor Other Hyperkinet Mov (N Y). 2020 Jul 9;10:21. doi: 10.5334/tohm.536. PMID: 32775035.
60. Carlozzi NE, Boileau NR, Roberts A, Dayalu P, Hanifan DL, Miner JA, Claassen D, Provost EM. **Understanding speech and swallowing difficulties in individuals with Huntington disease: Validation of the HDQLIFE Speech Difficulties and Swallowing Difficulties Item Banks.** Qual Life Res. 2020 Aug 24. doi: 10.1007/s11136-020-02608-0. PMID: 32839864.
61. Lu AT, Narayan P, Grant MJ, Langfelder P, Wang N, Kwak S, Wilkinson H, Chen RZ, Chen J, Simon Bawden C, Rudiger SR, Ciosi M, Chatzi A, Maxwell A, Hore TA, Aaronson J, Rosinski J, Preiss A, Vogt TF, Coppola G, Monckton D, Snell RG, William Yang X, Horvath S. **DNA methylation study of Huntington's disease and motor progression in patients and in animal models.** Nat Commun. 2020 Sep 10;11(1):4529. doi: 10.1038/s41467-020-18255-5. PMID: 32913184.
62. Schultz JL, Moser AD, Nopoulos PC. **The Association between CAG Repeat Length and Age of Onset of Juvenile-Onset Huntington's Disease.** Brain Sci. 2020 Aug 20;10(9):E575. doi: 10.3390/brainsci10090575. PMID: 32825467.

Publications that have used Enroll-HD data

63. Ranganathan M, Kostyk SK, Allain DC, Race JA, Daley AM. **Age of Onset and Behavioral Manifestations in Huntington's Disease: An Enroll-HD Cohort Analysis.** Clin Genet. 2021 January. doi: 10.1111/cge.13857. PMID: 33020896.
64. Langbehn DR, Hersch S. **Clinical Outcomes and Selection Criteria for Prodromal Huntington's Disease Trials.** Mov Disord. 2020 Jul 20. doi: 10.1002/mds.28222. PMID: 32686867.
65. Mühlbäck A, Frank W, Klempířová O, Bezdíček O, Schmitt L, Hofstetter N, Landwehrmeyer GB, Klempíř J. **Validation Study of a German Cognitive Battery for Huntington's Disease: Relationship Between Cognitive Performance, Functional Decline, and Disease Burden.** Arch Clin Neuropsychol. 2020 Jul 1:acaa038. doi: 10.1093/arclin/acaa038. PMID: 32613239.
66. Ogilvie AC, Gonzalez-Alegre P, Schultz JL. **Diabetes Mellitus Is Associated With an Earlier Age of Onset of Huntington's Disease.** Mov Disord. 2020 Dec 24. doi: 10.1002/mds.28460. PMID: 33368647.
67. Griffin BA, Booth MS, Busse M, Wild EJ, Setodji C, Warner JH, Sampaio C, Mohan A. **Estimating the causal effects of modifiable, non-genetic factors on Huntington disease progression using propensity score weighting.** Parkinsonism Relat Disord. 2021 Jan 13;83:56-62. doi: 10.1016/j.parkreldis.2021.01.010. PMID: 33476879.
68. van der Zwaan KF, Jacobs M, van Zwet EW, Roos RAC, de Bot ST. **Predictors of Working Capacity Changes Related to Huntington's Disease: A Longitudinal Study.** J Huntingtons Dis. 2021 Jan 26. doi: 10.3233/JHD-200446. PMID: 33523014.
69. Schultz JL, Saft C, Nopoulos PC. **Association of CAG Repeat Length in the Huntington Gene With Cognitive Performance in Young Adults.** Neurology. 2021 Mar 10:10.1212/WNL.0000000000011823. doi: 10.1212/WNL.0000000000011823. PMID: 33692166.
70. Achenbach J, Saft C, Faissner S. **Longitudinal Evaluation of the Effect of Tricyclic Antidepressants and Neuroleptics on the Course of Huntington's Disease-Data from a Real World Cohort.** Brain Sci. 2021 Mar 25;11(4):413. doi: 10.3390/brainsci11040413. PMID: 33805940.
71. Oosterloo M, de Greef BTA, Bijlsma EK, Durr A, Tabrizi SJ, Estevez-Fraga C, de Die-Smulders CEM, Roos RAC. **Disease Onset in Huntington's Disease: When Is the Conversion?** Mov Disord Clin Pract. 2021 Jan 31;8(3):352-360. doi: 10.1002/mdc3.13148. PMID: 33816663, PMC8015887.
72. Hentosh S, Zhu L, Patino J, Furr JW, Rocha NP, Furr Stimming E. **Sex Differences in Huntington's Disease: Evaluating the Enroll-HD Database.** Mov Disord Clin Pract. 2021 Mar 8;8(3):420-426. doi: 10.1002/mdc3.13178. PMID: 33816672, PMC8015889.
73. Achenbach J, Saft C. **Data from ENROLL-HD: Is the prevalence of juvenile and pediatric Huntington's disease overestimated?** Parkinsonism Relat Disord. 2021 May 20;88:1-2. doi: 10.1016/j.parkreldis.2021.05.012. PMID: 34049236.
74. Achenbach J, Faissner S, Saft C. **Differential Diagnosis of Chorea-HIV Infection Delays Diagnosis of Huntington's Disease by Years.** Brain Sci. 2021 May 27;11(6):710. doi: 10.3390/brainsci11060710. PMID: 34071882.

Publications that have used Enroll-HD data

75. Symonds AL, Macerollo A, Foy K, Alusi SH, Davies R. **Genetic and Environmental Contributors to Neurodegeneration: An Exploration of the Effects of Alcohol on Clinical Features of Huntington's Disease Using the Enroll-HD Global Platform.** Int J Environ Res Public Health. 2021 May 12;18(10):5113. doi: 10.3390/ijerph18105113. PMID: 34065918.
76. Ghazaleh N, Houghton R, Palermo G, Schobel SA, Wijeratne PA, Long JD. **Ranking the Predictive Power of Clinical and Biological Features Associated With Disease Progression in Huntington's Disease.** Front Neurol. 2021 May 20;12:678484. doi: 10.3389/fneur.2021.678484. PMID: 34093422; PMCID: PMC8176643.
77. Sprenger GP, Roos RAC, van Zwet E, Reijntjes RH, Achterberg WP, de Bot ST. **The prevalence of pain in Huntington's disease in a large worldwide cohort.** Parkinsonism Relat Disord. 2021 Jun 19;89:73-78. doi: 10.1016/j.parkreldis.2021.06.015. PMID: 34243026.
78. Abreu D, Ware J, Georgiou-Karistianis N, Leavitt BR, Fitzer-Attas CJ, Lobo R, Fernandes AR, Handley O, Anderson KE, Stout JC, Sampaio C. **Utility of Huntington's Disease Assessments by Disease Stage: Floor/Ceiling Effects.** Front Neurol. 2021 Jul 15;12:595679. doi: 10.3389/fneur.2021.595679. PMID: 34335433; PMCID: PMC8320772.
79. Crowell V, Houghton R, Tomar A, Fernandes T, Squitieri F. **Modeling Manifest Huntington's Disease Prevalence Using Diagnosed Incidence and Survival Time.** Neuroepidemiology. 2021 Jul 15:1-8. doi: 10.1159/000516767. PMID: 34350853.
80. Ogilvie AC, Nopoulos PC, Schultz JL. **Sleep disturbances by disease type and stage in Huntington's disease.** Parkinsonism Relat Disord. 2021 Aug 21;91:13-18. doi: 10.1016/j.parkreldis.2021.08.011. PMID: 34450461.
81. van Duijn E, Fernandes AR, Abreu D, Ware JJ, Neacy E, Sampaio C. **Incidence of completed suicide and suicide attempts in a global prospective study of Huntington's disease.** BJPsych Open. 2021 Aug 31;7(5):e158. doi: 10.1192/bjo.2021.969. PMID: 34462049.
82. Sathe S, Ware J, Levey J, Neacy E, Blumenstein R, Noble S, Mühlbäck A, Rosser A, Landwehrmeyer GB, Sampaio C. **Enroll-HD: An Integrated Clinical Research Platform and Worldwide Observational Study for Huntington's Disease.** Front Neurol. 2021 Aug 18;12:667420. doi: 10.3389/fneur.2021.667420. PMID: 34484094; PMCID: PMC8416308.
83. McDonnell EI, Wang Y, Goldman J, Marder K. **Age of Onset of Huntington's Disease in Carriers of Reduced Penetrance Alleles.** Mov Disord. 2021 Sep 18. doi: 10.1002/mds.28789. PMID: 34536046.
84. Panegyres PK, Chen HY. **Alzheimer's disease, Huntington's disease and cancer.** J Clin Neurosci. 2021 Nov;93:103-105. doi: 10.1016/j.jocn.2021.09.012. PMID: 34656231.
85. Ogilvie AC, Nopoulos PC, Schultz JL. **Quantifying the Onset of Unintended Weight Loss in Huntington's Disease: A Retrospective Analysis of Enroll-HD.** J Huntingtons Dis. 2021 Oct 4. doi: 10.3233/JHD-210488. PMID: 34633327.

Publications that have used Enroll-HD data

86. Cain KK, Flanigan JL, Dalrymple WA, Patrie J, Harrison MB, Barrett MJ. **The Effect of Education on Symptom Onset and Severity of Huntington's Disease.** *Mov Disord Clin Pract.* 2021 Mar 30;8(4):555-562. doi: 10.1002/mdc3.13195. PMID: 33981788; PMCID: PMC8088098.
87. Lang C, Gries C, Lindenberg KS, Lewerenz J, Uhl S, Olsson C, Samzelius J, Landwehrmeyer GB. **Monitoring the Motor Phenotype in Huntington's Disease by Analysis of Keyboard Typing During Real Life Computer Use.** *J Huntingtons Dis.* 2021;10(2):259-268. doi: 10.3233/JHD-200451. PMID: 33459656.
88. Mohan A, Sun Z, Ghosh S, Li Y, Sathe S, Hu J, Sampaio C. **A Machine-Learning Derived Huntington's Disease Progression Model: Insights for Clinical Trial Design.** *Mov Disord.* 2021 Dec 6. doi: 10.1002/mds.28866. PMID: 34870344.
89. Achenbach J, Saft C. **Another Perspective on Huntington's Disease: Disease Burden in Family Members and Pre-Manifest HD When Compared to Genotype-Negative Participants from ENROLL-HD.** *Brain Sci.* 2021 Dec 8;11(12):1621. doi: 10.3390/brainsci11121621. PMID: 34942923; PMCID: PMC8699274.
90. McLaren B, Andrews SC, Glikmann-Johnston Y, Mercieca EC, Murray NWG, Loy C, Bellgrove MA, Stout JC. **Feasibility and initial validation of 'HD-Mobile', a smartphone application for remote self-administration of performance-based cognitive measures in Huntington's disease.** *J Neurol.* 2021 Feb;268(2):590-601. doi: 10.1007/s00415-020-10169-y. PMID: 32880724.
91. Lunven M, Hamet Bagnou J, Youssov K, Gabadinho A, Fliss R, Montillot J, Audureau E, Bapst B, Morgado G, Reilmann R, Schubert R, Busse M, Craufurd D, Massart R, Rosser A, Bachoud-Lévi AC. **Cognitive decline in Huntington's disease in the Digitalized Arithmetic Task (DAT).** *PLoS One.* 2021 Aug 23;16(8):e0253064. doi: 10.1371/journal.pone.0253064. PMID: 34424902; PMCID: PMC8382187.
92. Harris KL, Mason SL, Barker RA. **Exploring the predictors of financial impairment in Huntington's disease using the Enroll-HD dataset.** *J Neurol.* 2022 Feb 14. doi: 10.1007/s00415-021-10929-4. PMID: 35165768.
93. Langbehn DR, Fine EM, Meier A, Hersch S. **Utility of the Huntington's Disease Prognostic Index Score for a Perimanifest Clinical Trial.** *Mov Disord.* 2022 Feb 16. doi: 10.1002/mds.28944. PMID: 35170086.
94. Rodrigues FB, Owen G, Sathe S, Pak E, Kaur D, Ehrhardt AG, Lifer S, Townhill J, Schubert K, Leavitt BR, Guttman M, Bang J, Lewerenz J, Levey J; HDClarity Investigators, Sampaio C, Wild EJ. **Safety and Feasibility of Research Lumbar Puncture in Huntington's Disease: The HDClarity Cohort and Bioresource.** *J Huntingtons Dis.* 2022;11(1):59-69. doi: 10.3233/JHD-210508. PMID: 35253773.
95. Lee JM, Huang Y, Orth M, Gillis T, Siciliano J, Hong E, Mysore JS, Lucente D, Wheeler VC, Seong IS, McLean ZL, Mills JA, McAllister B, Lobanov SV, Massey TH, Ciosi M, Landwehrmeyer GB, Paulsen JS, Dorsey ER, Shoulson I, Sampaio C, Monckton DG, Kwak S, Holmans P, Jones L, MacDonald ME, Long JD, Gusella JF. **Genetic modifiers of Huntington disease differentially influence motor and cognitive domains.** *Am J Hum Genet.* 2022 Mar 18:S0002-9297(22)00100-8. doi: 10.1016/j.ajhg.2022.03.004. PMID: 35325614.
96. Petracca M, Di Tella S, Solito M, Zinzi P, Lo Monaco MR, Di Lazzaro G, Calabresi P, Silveri MC, Bentivoglio AR. **Clinical and genetic characteristics of late-onset Huntington's disease in a large European cohort.** *Eur J Neurol.* 2022 Mar 31. doi: 10.1111/ene.15340. PMID: 35357736.

Publications that have used Enroll-HD data

97. Maltby J, Ovaska-Stafford N, Gunn S. **The structure of mental health symptoms in Huntington's disease: Comparisons with healthy populations.** J Clin Exp Neuropsychol. 2021 Sep;43(7):737-752. doi: 10.1080/13803395.2021.2002824. PMID: 34906020.
98. Warner JH, Long JD, Mills JA, Langbehn DR, Ware J, Mohan A, Sampaio C. **Standardizing the CAP Score in Huntington's Disease by Predicting Age-at-Onset.** J Huntingtons Dis. 2022 Apr 19. doi: 10.3233/JHD-210475. PMID: 35466943.
99. Rocha NP, Tuazon MR, Patino J, Furr Stimming E, Teixeira AL. **Clinical Correlates of Depression and Suicidality in Huntington Disease: An Analysis of the Enroll-HD Observational Study.** Cogn Behav Neurol. 2022 Apr 22. doi: 10.1097/WNN.0000000000000301. PMID: 35486527.
100. Achenbach J, Faissner S, Saft C. **Resurrection of sildenafil: potential for Huntington's Disease, too? J Neurol.** 2022 May 28. doi: 10.1007/s00415-022-11196-7. PMID: 35633374.
101. Achenbach J, Matusch A, Elmenhorst D, Bauer A, Saft C. **Divergent Effects of the Nonselective Adenosine Receptor Antagonist Caffeine in Pre-Manifest and Motor-Manifest Huntington's Disease.** Biomedicines. 2022 May 27;10(6):1258. doi: 10.3390/biomedicines10061258. PMID: 35740281.
102. Maffi S, Scaricamazza E, Migliore S, Casella M, Ceccarelli C, Squitieri F. **Sleep Quality and Related Clinical Manifestations in Huntington Disease.** J Pers Med. 2022 May 25;12(6):864. doi: 10.3390/jpm12060864. PMID: 35743649.
103. Quinn L, Playle R, Drew CJG, Taiyari K, Williams-Thomas R, Muratori LM, Hamana K, Griffin BA, Kelson M, Schubert R, Friel C, Morgan-Jones P, Rosser A, Busse M; PACE-HD site investigators. **Physical activity and exercise outcomes in Huntington's disease (PACE-HD): results of a 12-month trial-within-cohort feasibility study of a physical activity intervention in people with Huntington's disease.** Parkinsonism Relat Disord. 2022 Jun 29;101:75-89. doi: 10.1016/j.parkreldis.2022.06.013. PMID: 35809488.
104. Achenbach J, Saft C, Faissner S, Ellrichmann G. **Positive effect of immunomodulatory therapies on disease progression in Huntington's disease? Data from a real-world cohort.** Ther Adv Neurol Disord. 2022 Jul 23;15:17562864221109750. doi: 10.1177/17562864221109750. PMID: 35899100; PMCID: PMC9310279.
105. Tabrizi SJ, Schobel S, Gantman EC, Mansbach A, Borowsky B, Konstantinova P, Mestre TA, Panagoulas J, Ross CA, Zauderer M, Mullin AP, Romero K, Sivakumaran S, Turner EC, Long JD, Sampaio C; Huntington's Disease Regulatory Science Consortium (HD-RSC). **A biological classification of Huntington's disease: the Integrated Staging System.** Lancet Neurol. 2022 Jul;21(7):632-644. doi: 10.1016/S1474-4422(22)00120-X. PMID: 35716693.
106. Migliore S, D'Aurizio G, Maffi S, Ceccarelli C, Ristori G, Romano S, Castaldo A, Mariotti C, Curcio G, Squitieri F. **Cognitive and behavioral associated changes in manifest Huntington disease: A retrospective cross-sectional study.** Brain Behav. 2021 Jul;11(7):e02151. doi: 10.1002/brb3.2151. PMID: 34110097; PMCID: PMC8323039.

Publications that have used Enroll-HD data

107. Ogilvie AC, Carnahan RM, Chrischilles EA, Schultz JL. **The effects of antidepressants on depressive symptoms in manifest Huntington's disease.** J Psychosom Res. 2022 Aug 30;162:111023. doi: 10.1016/j.jpsychores.2022.111023. PMID: 36063627.
108. Squitieri F, Monti L, Graziola F, Colafati GS, Sabatini U. **Early liver steatosis in children with pediatric Huntington disease and highly expanded CAG mutations.** Parkinsonism Relat Disord. 2022 Aug 28;103:102-104. doi: 10.1016/j.parkreldis.2022.08.027. PMID: 36096016.
109. Fang L, Monteys AM, Dürr A, Keiser M, Cheng C, Harapanahalli A, Gonzalez-Alegre P, Davidson BL, Wang K. **Haplotyping SNPs for allele-specific gene editing of the expanded huntingtin allele using long-read sequencing.** HGG Adv. 2022 Sep 26;4(1):100146. doi: 10.1016/j.xhgg.2022.100146. PMID: 36262216; PMCID: PMC9574884.
110. Koval I, Dighiero-Brecht T, Tobin AJ, Tabrizi SJ, Scahill RI, Tezenas du Montcel S, Durrleman S, Durr A. **Forecasting individual progression trajectories in Huntington disease enables more powered clinical trials.** Sci Rep. 2022 Nov 7;12(1):18928. doi: 10.1038/s41598-022-18848-8. PMID: 36344508.
111. Scarabino D, Veneziano L, Mantuano E, Arisi I, Fiore A, Frontali M, Corbo RM. **Leukocyte Telomere Length as Potential Biomarker of HD Progression: A Follow-Up Study.** Int J Mol Sci. 2022 Nov 3;23(21):13449. doi: 10.3390/ijms232113449. PMID: 36362235.
112. Andriessen RL, Oosterloo M, Hollands A, Linden DEJ, de Greef BTA, Leentjens AFG. **Psychotropic medication use in Huntington's disease: A retrospective cohort study.** Parkinsonism Relat Disord. 2022 Nov 7;105:69-74. doi: 10.1016/j.parkreldis.2022.11.004. PMID: 36379156.
113. Stoebner ZA, Hett K, Lyu I, Johnson H, Paulsen JS, Long JD, Oguz I. **Comprehensive shape analysis of the cortex in Huntington's disease.** Hum Brain Mapp. 2022 Nov 21. doi: 10.1002/hbm.26125. PMID: 36409662.
114. McLauchlan DJ, Lancaster T, Craufurd D, Linden DEJ, Rosser AE. **Different depression: motivational anhedonia governs antidepressant efficacy in Huntington's disease.** Brain Commun. 2022 Nov 9;4(6):fcac278. doi: 10.1093/braincomms/fcac278. PMID: 36440100; PMCID: PMC9683390.
115. Ruiz-Idiago J, Pomarol-Clotet E, Salvador R. **Longitudinal analysis of neuropsychiatric symptoms in a large cohort of early-moderate manifest Huntington's disease patients.** Parkinsonism Relat Disord. 2022 Nov 22;106:105228. doi: 10.1016/j.parkreldis.2022.11.020. PMID: 36470173.
116. Di Tella S, Lo Monaco MR, Petracca M, Zinzi P, Solito M, Piano C, Calabresi P, Silveri MC, Bentivoglio AR. **Beyond the CAG triplet number: exploring potential predictors of delayed age of onset in Huntington's disease.** J Neurol. 2022 Dec;269(12):6634-6640. doi: 10.1007/s00415-022-11297-3. PMID: 35915275.
117. Sokol LL, Nance M, Kluger BM, Yeh C, Paulsen JS, Smith AK, Bega D. **Factors Associated with the Place of Death in Huntington Disease: Analysis of Enroll-HD.** J Palliat Med. 2023 Jan 27. doi: 10.1089/jpm.2022.0143. PMID: 36706436.
118. Ko J, Furby H, Ma X, Long JD, Lu XY, Slowiejko D, Gandhi R. **Clustering and prediction of disease progression trajectories in Huntington's disease: An analysis of Enroll-HD data using a machine learning**

Publications that have used Enroll-HD data

approach. Front Neurol. 2023 Jan 30;13:1034269. doi: 10.3389/fneur.2022.1034269. PMID: 36793800; PMCID: PMC9923354.

119. Gunn S, Dale M, Ovaska-Stafford N, Maltby J. **Mental health symptoms among those affected by Huntington's disease: A cross-sectional study.** Brain Behav. 2023 Mar 6:e2954. doi: 10.1002/brb3.2954. PMID: 36880126.
120. Lunven M, Hernandez Dominguez K, Youssov K, Hamet Bagnou J, Fliss R, Vandendriessche H, Bapst B, Morgado G, Remy P, Schubert R, Reilmann R, Busse M, Craufurd D, Massart R, Rosser A, Bachoud-Lévi AC. **A new approach to digitized cognitive monitoring: validity of the SelfCog in Huntington's disease.** Brain Commun. 2023 Mar 6;5(2):fcad043. doi: 10.1093/braincomms/fcad043. PMID: 36938527; PMCID: PMC10018460.
121. Ruiz de Sabando A, Urrutia Lafuente E, Galbete A, Ciosi M, García Amigot F, García Solaesa V; Spanish HD Collaborative group; Monckton DG, Ramos-Arroyo MA. **Spanish HTT gene study reveals haplotype and allelic diversity with possible implications for germline expansion dynamics in Huntington disease.** Hum Mol Genet. 2023 Mar 6;32(6):897-906. doi: 10.1093/hmg/ddac224. PMID: 36130218; PMCID: PMC9990985.
122. Long JD, Gantman EC, Mills JA, Vaidya JG, Mansbach A, Tabrizi SJ, Sampaio C. **Applying the Huntington's Disease Integrated Staging System (HD-ISS) to Observational Studies.** J Huntingtons Dis. 2023 Apr 17. doi: 10.3233/JHD-220555. PMID: 37092230.
123. Hamilton JL, Mills JA, Stebbins GT, Long JD, Fuller RLM, Sathe S, Roché M, Sampaio C. **Defining Clinical Meaningfulness in Huntington's Disease.** Mov Disord. 2023 May 5. doi: 10.1002/mds.29394. PMID: 37147862.
124. Heinzmann A, Sayah S, Lejeune FX, Hahn V, Teichmann M, Monin ML, Marchionni E, Gérard F, Charles P, Pariente J, Durr A. **Huntington's Disease with Small CAG Repeat Expansions.** Mov Disord. 2023 Jun 8. doi: 10.1002/mds.29427. PMID: 37288993.
125. Ogilvie AC, Schultz JL. **Memantine Use and Cognitive Decline in Huntington's Disease: An Enroll-HD Study.** Mov Disord Clin Pract. 2023 May 16;10(7):1120-1125. doi: 10.1002/mdc3.13763. PMID: 37476323; PMCID: PMC10354618.
126. Martínez-Horta S, Perez-Perez J, Oltra-Cucarella J, Sampedro F, Horta-Barba A, Puig-Davi A, Pagonabarraga J, Kulisevsky J. **Divergent cognitive trajectories in early stage Huntington's disease: A 3-year longitudinal study.** Eur J Neurol. 2023 Jul;30(7):1871-1879. doi: 10.1111/ene.15806. PMID: 36994811.
127. Sierra LA, Ullman CJ, Baselga-Garriga C, Pandeya SR, Frank SA, Laganieri S. **Prevalence of neurocognitive disorder in Huntington's disease using the Enroll-HD dataset.** Front Neurol. 2023 Jul 14;14:1198145. doi: 10.3389/fneur.2023.1198145. PMID: 37521291; PMCID: PMC10375015.
128. Horta-Barba A, Martinez-Horta S, Pérez-Pérez J, Puig-Davi A, de Lucia N, de Michele G, Salvatore E, Kehrer S, Priller J, Migliore S, Squitieri F, Castaldo A, Mariotti C, Mañanes V, Lopez-Sendon JL, Rodriguez N, Martinez-Descals A, Júlio F, Januário C, Delussi M, de Tommaso M, Noguera S, Ruiz-Idiago J, Sitek EJ, Wallner R, Nuzzi A, Pagonabarraga J, Kulisevsky J; Cognitive Phenotype Working Group of the European

Publications that have used Enroll-HD data

Huntington's Disease Network. **Measuring cognitive impairment and monitoring cognitive decline in Huntington's disease: a comparison of assessment instruments.** J Neurol. 2023 Jul 18. doi: 10.1007/s00415-023-11804-0. PMID: 37462754.

129. Ouwerkerk J, Feleus S, van der Zwaan KF, Li Y, Roos M, van Roon-Mom WMC, de Bot ST, Wolstencroft KJ, Mina E. **Machine learning in Huntington's disease: exploring the Enroll-HD dataset for prognosis and driving capability prediction.** Orphanet J Rare Dis. 2023 Jul 27;18(1):218. doi: 10.1186/s13023-023-02785-4. PMID: 37501188; PMCID: PMC10375780.
130. Buchanan DA, Brown AE, Osigwe EC, Pfalzer AC, Mann LG, Yan Y, Kang H, Claassen DO. **Racial Differences in the Presentation and Progression of Huntington's Disease.** Mov Disord. 2023 Aug 10. doi: 10.1002/mds.29536. PMID: 37559498.
131. Mühlbäck A, Mana J, Wallner M, Frank W, Lindenberg KS, Hoffmann R, Klempířová O, Klempíř J, Landwehrmeyer GB, Bezdicek O; REGISTRY investigators of the European Huntington's Disease Network, the Enroll-HD investigators. **Establishing normative data for the evaluation of cognitive performance in Huntington's disease considering the impact of gender, age, language, and education.** J Neurol. 2023 Oct;270(10):4903-4913. doi: 10.1007/s00415-023-11823-x. PMID: 37347292; PMCID: PMC10511566.
132. Pfalzer AC, Watson KH, Ciriegio AE, Hale L, Diehl S, McDonnell KE, Vnencak-Jones C, Huitz E, Snow A, Roth MC, Guthrie CS, Riordan H, Long JD, Compas BE, Claassen DO. **Impairments to executive function in emerging adults with Huntington disease.** J Neurol Neurosurg Psychiatry. 2023 Feb;94(2):130-135. doi: 10.1136/jnnp-2022-329812. PMID: 36450478.
133. Jeyakumar N, Hilmer SN, Teixeira-Pinto A, Loy CT. **Frailty and Associated Environmental Factors Only Have Small Effects on Age of Onset in Huntington's Disease.** J Huntingtons Dis. 2023 Nov 24. doi: 10.3233/JHD-230572. PMID: 38007671.
134. Langbehn DR, Sathe SS, Loy C, Sampaio C, Mccusker EA. **A Phenotypic Atlas for Huntington Disease Based on Data From the Enroll-HD Cohort Study.** Neurol Genet. 2023 Nov 28;9(6):e200111. doi: 10.1212/NXG.0000000000200111. PMID: 38035176; PMCID: PMC10684052.
135. Mendizabal A, Singh AP, Perlman S, Brown A, Bordelon Y. **Disparities in Huntington Disease Severity: Analysis Using the ENROLL-HD Dataset.** Neurol Clin Pract. 2023 Dec;13(6):e200200. doi: 10.1212/CPJ.0000000000200200. PMID: 37795504; PMCID: PMC10547468.
136. Nopoulos S, Reasoner EE, Ogilvie AC, Killoran A, Schultz JL. **Evaluating motor progression of juvenile-onset Huntington's Disease: An Enroll-HD analysis.** Parkinsonism Relat Disord. 2024 Feb;119:105954. doi: 10.1016/j.parkreldis.2023.105954. PMID: 38142629.
137. Achenbach J, Stodt B, Saft C. **Factors Influencing the Total Functional Capacity Score as a Critical Endpoint in Huntington's Disease Research.** Biomedicines. 2023 Dec 17;11(12):3336. doi: 10.3390/biomedicines11123336. PMID: 38137557; PMCID: PMC10741795.
138. Migliore S, Bianco SD, Scocchia M, Maffi S, Busi LC, Ceccarelli C, Curcio G, Mazza T, Squitieri F. **Prodromal Cognitive Changes as a Prognostic Indicator of Forthcoming Huntington's Disease Severity: A Retrospective Longitudinal Study.** Mov Disord Clin Pract. 2024 Jan 24. doi: 10.1002/mdc3.13975. PMID: 38264920.

Publications that have used Enroll-HD data

139. Sun Z, Ware J, Dey S, Eyigoz E, Sathe S, Sampaio C, Hu J. **Large-scale screening of clinical assessments to distinguish between states in the Integrated HD Progression Model (IHDPM).** Front Aging Neurosci. 2024 Feb 13;16:1320755. doi: 10.3389/fnagi.2024.1320755. PMID: 38414632; PMCID: PMC10896990.
140. Gaudet ID, Xu H, Gordon E, Cannestro GA, Lu ML, Wei J. **Elevated SLC7A2 expression is associated with an abnormal neuroinflammatory response and nitrosative stress in Huntington's disease.** J Neuroinflammation. 2024 Feb 28;21(1):59. doi: 10.1186/s12974-024-03038-2. PMID: 38419038; PMCID: PMC10900710.
141. Pflazer AC, Shiino S, Silverman J, Codreanu SG, Sherrod SD, McLean JA, Claassen DO. **Alterations in Cerebrospinal Fluid Urea Occur in Late Manifest Huntington's Disease.** J Huntingtons Dis. 2024 Mar 2. doi: 10.3233/JHD-231511. PMID: 38461512.
142. Knights H, Coleman A, Hobbs NZ, Tabrizi SJ, Scahill RI; HD-YAS investigators. **Freesurfer Software Update Significantly Impacts Striatal Volumes in the Huntington's Disease Young Adult Study and Will Influence HD-ISS Staging.** J Huntingtons Dis. 2024;13(1):77-90. doi: 10.3233/JHD-231512. PMID: 38489194.
143. Delussi M, Valt C, Silvestri A, Ricci K, Ladisa E, Ammendola E, Rampino A, Pergola G, de Tommaso M. **Auditory mismatch negativity in pre-manifest and manifest Huntington's disease.** Clin Neurophysiol. 2024 Mar 26;162:121-128. doi: 10.1016/j.clinph.2024.03.020. PMID: 38603947.
144. Fahed VS, Doheny EP, Collazo C, Krzysztofik J, Mann E, Morgan-Jones P, Mills L, Drew C, Rosser AE, Cousins R, Witkowski G, Cubo E, Busse M, Lowery MM. **Language-Independent Acoustic Biomarkers for Quantifying Speech Impairment in Huntington's Disease.** Am J Speech Lang Pathol. 2024 Mar 26:1-16. doi: 10.1044/2024_AJSLP-23-00175. PMID: 38530396.
145. Lozano-Garcia M, Doheny EP, Mann E, Morgan-Jones P, Drew C, Busse-Morris M, Lowery MM. **Estimation of Gait Parameters in Huntington's Disease using Wearable Sensors in the Clinic and Free-living Conditions.** IEEE Trans Neural Syst Rehabil Eng. 2024 May 31;PP. doi: 10.1109/TNSRE.2024.3407887. PMID: 38819972.
146. Raschka T, Li Z, Gaßner H, Kohl Z, Jukic J, Marxreiter F, Fröhlich H. **Unraveling progression subtypes in people with Huntington's disease.** EPMA J. 2024 May 28;15(2):275-287. doi: 10.1007/s13167-024-00368-2. PMID: 38841617; PMCID: PMC11148000.
147. Gil-Salcedo A, Massart R, de Langavant LC, Bachoud-Levi AC. **Modifiable factors associated with Huntington's disease progression in presymptomatic participants.** Ann Clin Transl Neurol. 2024 Jun 10. doi: 10.1002/acn3.52120. PMID: 38855890.
148. Sprenger GP, van Zwet EW, Bakels HS, Achterberg WP, Roos RA, de Bot ST. **Prevalence and burden of pain across the entire spectrum of Huntington's disease.** J Neurol Neurosurg Psychiatry. 2024 Jun 17;95(7):647-655. doi: 10.1136/jnnp-2023-332992. PMID: 38290837.
149. Ruiz de Sabando A, Ciosi M, Galbete A, Cumming SA; Spanish HD Collaborative Group; Monckton DG, Ramos-Arroyo MA. **Somatic CAG repeat instability in intermediate alleles of the HTT gene and its**

Publications that have used Enroll-HD data

- potential association with a clinical phenotype.** Eur J Hum Genet. 2024 Jul;32(7):770-778. doi: 10.1038/s41431-024-01546-6. PMID: 38433266; PMCID: PMC11220145.
150. Ioakeimidis V, Busse M, Drew CJG, Pallmann P, Watson GB, Jones D, Palombo M, Schubert R, Rosser AE, Metzler-Baddeley C. **Protocol for a randomised controlled unblinded feasibility trial of HD-DRUM: a rhythmic movement training application for cognitive and motor symptoms in people with Huntington's disease.** BMJ Open. 2024 Jul 31;14(7):e082161. doi: 10.1136/bmjopen-2023-082161. PMID: 39089721.
 151. Bakels HS, Feleus S, Rodríguez-Girondo M, Losekoot M, Bijlsma EK, Roos RAC, de Bot ST. **Prevalence of Juvenile-Onset and Pediatric Huntington's Disease and Their Availability and Ability to Participate in Trials: A Dutch Population and Enroll-HD Observational Study.** J Huntingtons Dis. 2024 Aug 3. doi: 10.3233/JHD-240034. PMID: 39121132.
 152. Guzauskas GF, Tabrizi SJ, Long JD, Arnesen A, Hamilton JL, Claassen DO, Munetsi LR, Malik S, Rodríguez-Santana I, Ali TM, Zhang F. **Long-Term Health Outcomes of Huntington Disease and the Impact of Future Disease-Modifying Treatments: A Decision-Modeling Analysis.** Neurol Clin Pract. 2024 Oct;14(5):e200340. doi: 10.1212/CPJ.0000000000200340. Epub 2024 Aug 15. PMID: 39161748; PMCID: PMC11332983.
 153. Schoenmakers DH, van den Berg S, Timmers L, Adang LA, Bäumer T, Bosch A, van de Castele M, Datema MR, Dekker H, Donnelly C, Driessens MHE, Graessner H, Greger V, Haddad T, Höglinger GU, van den Hout H, Jonker C, Langeveld M, Lambert LJ, Neacy E, Nieuwland M, Klockgether T, van der Knaap MS, Papadopoulou A, Plueschke K, van Rijn S, Rosenberg N, Saunier-Vivar EF, Dos Santos Vieira B, Hollak CEM, Goettsch WG, Wolf NI. **Framework for Multistakeholder Patient Registries in the Field of Rare Diseases: Focus on Neurogenetic Diseases.** Neurology. 2024 Sep 24;103(6):e209743. doi: 10.1212/WNL.0000000000209743. PMID: 39173102.
 154. Gray SM, Dai J, Smith AC, Beckley JT, Rahmati N, Lewis MC, Quirk MC. **Changes in 24(S)-Hydroxycholesterol Are Associated with Cognitive Performance in Early Huntington's Disease: Data from the TRACK and ENROLL HD Cohorts.** J Huntingtons Dis. 2024 Sep 5. doi: 10.3233/JHD-240030. PMID: 39269850.
 155. Di Cecca A, Ilardi CR, Della Pia F, Criscuolo C, Della Sala S, Salvatore E. **Distortion errors characterise visuo-constructive performance in Huntington's disease.** Clin Neuropsychol. 2024 Oct 11:1-19. doi: 10.1080/13854046.2024.2411740. PMID: 39394675.
 156. Mendizabal A, Ogilvie AC, Bordelon Y, Perlman SL, Brown A. **Racial Disparities in Time to Huntington Disease Diagnosis in North America: An ENROLL-HD Analysis.** Neurol Clin Pract. 2024 Oct;14(5):e200344. doi: 10.1212/CPJ.0000000000200344. PMID: 39872293; PMCID: PMC11771962.
 157. Feleus S, Skotnicki LEM, Roos RAC, de Bot ST. **Medication Use and Treatment Indications in Huntington's Disease; Analyses from a Large Cohort.** Mov Disord Clin Pract. 2024 Oct 21. doi: 10.1002/mdc3.14230. PMID: 39431460.
 158. Mills JA, Long JD, Vaidya JG, Gantman EC, Sathe S, Tabrizi SJ, Sampaio C. **Time to Functional Loss as an Endpoint in Huntington's Disease Trials: Enrichment and Sample Size.** Mov Disord. 2024 Oct;39(10):1809-1816. doi: 10.1002/mds.29963. PMID: 39101272.

Publications that have used Enroll-HD data

159. Funcis A, Ravera B, Zinzi P, Solito M, Petracca M, Calabresi P, Bentivoglio AR. **Neuroleptic malignant syndrome in Huntington disease.** Eur J Neurol. 2024 Oct 23:e16442. doi: 10.1111/ene.16442. PMID: 39444167.
160. Pollard A, Greetham D, Myatt J, Rickards H, Stanley C, Dungate D. **Data-driven Huntington's disease progression modelling and estimation of societal cost in the UK.** R Soc Open Sci. 2024 Nov 20;11(11):240824. doi: 10.1098/rsos.240824. PMID: 39569347; PMCID: PMC11576117.
161. Yao J, Feng B S G, Shao M S G, Mendizabal A, Telesca D, Fang K, Ibragimova L, Shoaib J, Morrison MA, Lupo JM. **Interplay between Sex and Disease Burden in Huntington's Disease: Clinical and Neuroimaging Perspectives.** medRxiv [Preprint]. 2024 Nov 2:2024.10.31.24315900. doi: 10.1101/2024.10.31.24315900. PMID: 39574844; PMCID: PMC11581089.
162. Schultz JL, Ogilvie AC, Harshman LA, Nopoulos PC. **β -Blocker Use and Delayed Onset and Progression of Huntington Disease.** JAMA Neurol. 2024 Dec 2. doi: 10.1001/jamaneurol.2024.4108. PMID: 39621338.
163. Feleus S, Vo MTD, Kuijper LCM, Roos RAC, de Bot ST. **Cognitive impairment predicts medication discrepancies in Huntington's Disease: patient self-report compared to pharmacy records.** J Neurol. 2024 Dec 12;272(1):55. doi: 10.1007/s00415-024-12728-z. PMID: 39665851.
164. Khetarpal V, Herbst T, Dominguez C, Munoz-Sanjuan I, Sampaio C, Marks B, Miller D, Farnham J, Ledvina A, Anglehart H, Rehmani I, LaFayette A, Spridco N, Langbehn D, Wild EJ, Pacifici R. **Lack of evidence for kynurenine pathway dysfunction in Huntington's disease: Cerebrospinal fluid and plasma analyses from the HDClarity study.** Journal of Huntington's Disease. Dec 10, 2024. doi:10.1177/18796397241301761.
165. van der Zwaan KF, Feleus S, Dekkers OM, Roos RAC, de Bot ST. **Total functioning capacity scale in Huntington's disease: natural course over time.** J Neurol. 2025 Jan 15;272(2):140. doi: 10.1007/s00415-024-12771-w. PMID: 39812810.
166. Gil-Salcedo A, Lunven M, Jacquemot C, Massart R, Bachoud-Levi AC. **Specific contribution of cognitive and motor impairments with functional capacity and dependence in Huntington's disease.** J Neurol. 2025 Feb 22;272(3):224. doi: 10.1007/s00415-025-12982-9. PMID: 39985726; PMCID: PMC11846732.
167. Geva M, Goldberg YP, Schuring H, Tan AM, Long JD, Hayden MR. **Antidopaminergic Medications and Clinical Changes in Measures of Huntington's Disease: A Causal Analysis.** Mov Disord. 2025 Mar 18. doi: 10.1002/mds.30164. PMID: 40099482.
168. Halabi N, Killoran A, Nopoulos PC, Schultz JL. **Differentiating Hyperkinetic and Hypokinetic Motor Features in the Progression of Huntington's Disease.** medRxiv [Preprint]. 2025 Apr 21:2025.04.17.25325819. doi: 10.1101/2025.04.17.25325819. PMID: 40313299; PMCID: PMC12045443.
169. Bakels HS, van der Zwaan KF, Van Zwet E, Reijntjes R, Sprenger GP, Knecht TA, Roos RAC, de Bot ST. **Comparison of the Clinical Spectrum of Juvenile- and Adult-Onset Huntington Disease: A National Cohort and Enroll-HD Observational Study.** Neurology. 2025 May 27;104(10):e213525. doi: 10.1212/WNL.0000000000213525. PMID: 40262071.

Publications that have used Enroll-HD data

170. Boareto M, Yamamoto Y, Long JD, Sampaio C, McColgan P, Diack C, Ducray PS. **Modeling Disease Progression and Placebo Response in Huntington Disease: Insights From Enroll-HD and GENERATION HD1 Cohorts.** *Neurology*. 2025 May 27;104(10):e213646. doi: 10.1212/WNL.0000000000213646. Epub 2025 May 2. PMID: 40315394.
171. Stimming EF, Claassen DO, Sen GP, Klepitskaya O, Serbin M, Kim H, Hinton SC, Haubenberger D. **Longitudinal Treatment Patterns of Chorea in North American Patients with Huntington's Disease: Data from Enroll-HD.** *Neurol Ther*. 2025 Jun;14(3):743-756. doi: 10.1007/s40120-024-00703-9. PMID: 39815077; PMCID: PMC12089624.
172. Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium. **Genetic modifiers of somatic expansion and clinical phenotypes in Huntington's disease highlight shared and tissue-specific effects.** *Nat Genet*. 2025 Jun;57(6):1426-1436. doi: 10.1038/s41588-025-02191-5. PMID: 40490511.
173. Yao J, Feng G, Shao G, Wang Z, Mendizabal A, Telesca D, Fang K, Ibragimova L, Shoaib J, Morrison MA, Lupo JM. **Interplay Between Sex and Cytosine-Adenine-Guanine-Age Product Score in Huntington's Disease: Clinical and Neuroimaging Perspectives.** *Mov Disord*. 2025 Sep 23. doi: 10.1002/mds.70064. PMID: 40985165.
174. Witkowski G, Zielonka D, Rola R, Sienkiewicz-Jarosz H. **The association between smoking and Huntington's disease symptom onset and progression - results from Enroll-HD: The observational cohort study of people with Huntington's disease.** *Neurol Neurochir Pol*. 2025 Oct 14. doi: 10.5603/pjnns.107176. PMID: 41084856.
175. Garcia-Forn M, Castany-Pladevall C, Creus-Muncunill J, Golbano A, Escaramís G, Pérez-Pérez J, Balantzategi U, Hernan-Godoy M, Brito V, Kulisevsky J, Martí E, Pérez-Navarro E. **Sertraline treatment prevents motor dysfunction in a Huntington's disease mouse model and functional decline in patients.** *Neurotherapeutics*. 2025 Oct;22(6):e00716. doi: 10.1016/j.neurot.2025.e00716. PMID: 40774881.
176. Knights H, Coleman A, Farag M, Leocadi M, Murphy M, Fayer K, Thackeray O, Langbehn D, Hobbs N, Tabrizi SJ, Scahill RI; HD-YAS investigators. **Bias in HD-ISS staging introduced by the FreeSurfer cross-sectional stream: Insights from the Huntington's Disease Young Adult Study (HD-YAS).** *J Huntingtons Dis*. 2025 Nov;14(4):396-402. doi: 10.1177/18796397251366900. PMID: 40801894; PMCID: PMC12602721.
177. Ghofrani-Jahromi M, Amirmoezzi Y, Abeyasinghe PM, Poudel GR, Razi A, Paulsen JS, Hobbs NZ, Scahill RI, Tabrizi SJ, Georgiou-Karistianis N, Saha S. **Mapping Regional Brain Aging in Huntington's Disease Using Structural Magnetic Resonance Imaging and Machine Learning.** *Mov Disord*. 2025 Dec 24. doi: 10.1002/mds.70160. Epub ahead of print. PMID: 41439586.
178. Hemicker G, Schwarzová K, Labrecque S, Cerejo C, Carbone F, Peball M, Wimmer B, Mahlknecht P, Krismer F, Djamshidian A, Seppi K, Heim B. **Bridging the gap: sex-specific differences in Huntington's disease.** *Orphanet J Rare Dis*. 2026 Jan 10. doi: 10.1186/s13023-025-04184-3. Epub ahead of print. PMID: 41520110.
179. Mclauchlan D, Drew C, Holmans P, Rosser A. **Exploring the association between antidepressants, progression and mortality in Huntington's disease.** *Brain*. 2026 Jan 21:awag009. doi: 10.1093/brain/awag009. Epub ahead of print. PMID: 41564085.